Stopping ACE-inhibitors in COVID-19

Phase 4, randomised, open-label trial in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Medical University of Innsbruck. Primary endpoints: Composite of the Maximum Sequential Organ Failure Assessment (SOFA) Score and Death Within 30 Days and Composite of Admission to an Intensive Care Unit (ICU), the Use of Mechanical Ventilation, or All-cause Death at 30 days. Started Apr 2020; status: completed.